European Society of Organ Transplantation (ESOT) Consensus Report on Downstaging, Bridging and Immunotherapy in Liver Transplantation for Hepatocellular Carcinoma
Transplant International · 14.09.2023 · 36
DOI: 10.3389/ti.2023.11648 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transplant International, online erschienen am 14.09.2023. Verfasst von Marco Petrus Adrianus Wilhelmus Claasen und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Division of HPB & Transplant Surgery, Erasmus MC Transplant Institute, University Medical Centre Rotterdam, Rotterdam, Netherl…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Liver Transplantation, Chemoembolization, Therapeutic. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 120 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Liver transplantation offers the best chance of cure for most patients with non-metastatic hepatocellular carcinoma (HCC). Although not all patients with HCC are eligible for liver transplantation at diagnosis, some can be downstaged using locoregional treatments such as ablation and transarterial chemoembolization. These aforementioned treatments are being applied as bridging therapies to keep patients within transplant criteria and to avoid them from dropping out of the waiting list while awaiting a liver transplant. Moreover, immunotherapy might have great potential to support downstaging and bridging therapies. To address the contemporary status of downstaging, bridging, and immunotherapy in liver transplantation for HCC, European Society of Organ Transplantation (ESOT) convened a dedicated working group comprised of experts in the treatment of HCC to review literature and to develop guidelines pertaining to this cause that were subsequently discussed and voted during the Transplant Learning Journey (TLJ) 3.0 Consensus Conference that took place in person in Prague. The findings and recommendations of the working group on Downstaging, Bridging and Immunotherapy in Liver Transplantation for Hepatocellular Carcinoma are presented in this article.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery, Division of HPB & Transplant Surgery, Erasmus MC Transplant Institute, University Medical Centre Rotterdam, Rotterdam, Netherlands.
- Multi-Organ Transplant Program, University Health Network (UHN), Toronto, ON, Canada.
- Centre Hépato-Biliaire, APHP Hôpital Universitaire Paul Brousse, Université Paris-Saclay, Paris, France.
- Hepatology, Hepato-Pancreato-Biliary Surgery and Liver Transplantation, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
- Chirurgia Generale 2, Epato-Bilio-Pancreatica e Centro Trapianto di Fegato, Azienda Ospedale Università Padova, Padova, Italy.
- General and Digestive Surgery, University Hospital La Paz, Madrid, Spain.
Zitieren
APA
Claasen, M. P. A. W., Sneiders, D., Rakké, Y. S., Adam, R., Bhoori, S., Cillo, U., Fondevila, C., Reig, M., Sapisochin, G., Tabrizian, P., & Toso, C. (2023). European Society of Organ Transplantation (ESOT) Consensus Report on Downstaging, Bridging and Immunotherapy in Liver Transplantation for Hepatocellular Carcinoma. Transplant International, 36. https://doi.org/10.3389/ti.2023.11648
Vancouver
Claasen MPAW, Sneiders D, Rakké YS, Adam R, Bhoori S, Cillo U, et al. European Society of Organ Transplantation (ESOT) Consensus Report on Downstaging, Bridging and Immunotherapy in Liver Transplantation for Hepatocellular Carcinoma. Transplant International. 2023;36. doi:10.3389/ti.2023.11648
BibTeX
@article{Claasen2023,
author = {Claasen, Marco Petrus Adrianus Wilhelmus and Sneiders, Dimitri and Rakké, Yannick Sebastiaan and Adam, René and Bhoori, Sherrie and Cillo, Umberto and Fondevila, Constantino and Reig, Maria and Sapisochin, Gonzalo and Tabrizian, Parissa and Toso, Christian},
title = {European Society of Organ Transplantation (ESOT) Consensus Report on Downstaging, Bridging and Immunotherapy in Liver Transplantation for Hepatocellular Carcinoma},
journal = {Transplant International},
year = {2023},
volume = {36},
doi = {10.3389/ti.2023.11648}
}
EUVIMED